Published in Br J Clin Pharmacol on January 01, 2003
Cigarette smoking behaviour and blood metabolomics. Int J Epidemiol (2015) 0.81
Caffeine Consumption Contributes to Skin Intrinsic Fluorescence in Type 1 Diabetes. Diabetes Technol Ther (2015) 0.81
CYP1A2, GSTM1, and GSTT1 polymorphisms and diet effects on CYP1A2 activity in a crossover feeding trial. Cancer Epidemiol Biomarkers Prev (2009) 0.81
Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected? Eur J Clin Pharmacol (2008) 0.80
Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure. Eur J Clin Pharmacol (2004) 0.76
Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol (1991) 2.35
Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics (1992) 2.02
A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol (1984) 1.99
Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther (1992) 1.51
The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther (1993) 1.51
Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics (1996) 1.41
A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther (1987) 1.37
Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping. Clin Pharmacol Ther (1998) 0.99
Genetic polymorphisms in xenobiotic metabolism. Eur J Cancer (1994) 0.99
Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol (1998) 0.95
Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Pharmacol Ther (1991) 0.94
Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers. Eur J Clin Pharmacol (1992) 0.93
Determination of drug-metabolizing enzyme activity in vivo: pharmacokinetic and statistical issues. Xenobiotica (1998) 0.90
Correlation between acetylation phenotype and genotype in Chinese women. Eur J Clin Pharmacol (2000) 0.84
Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity. Br J Clin Pharmacol (1995) 0.82
Acetylation polymorphism expression in patients before and after liver transplantation: influence of host/graft genotypes. Pharmacogenetics (1998) 0.82
Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow. Cancer Epidemiol Biomarkers Prev (1999) 0.81
Potential artifacts in the use of caffeine to determine acetylation phenotype. Br J Clin Pharmacol (1989) 0.81
Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities. Eur J Clin Pharmacol (1999) 0.81
Extractionless method for the simultaneous high-performance liquid chromatographic determination of urinary caffeine metabolites for N-acetyltransferase 2, cytochrome P450 1A2 and xanthine oxidase activity assessment. J Chromatogr B Biomed Sci Appl (2001) 0.80
Stability of 5-acetamido-6-formylamino-3-methyluracil in buffers and urine. J Pharm Biomed Anal (2002) 0.78
Acetylator phenotyping via analysis of four caffeine metabolites in human urine by micellar electrokinetic capillary chromatography with multiwavelength detection. Electrophoresis (1993) 0.78
Tacrine is not an ideal probe drug for measuring CYP1A2 activity in vivo. Br J Clin Pharmacol (1999) 0.78
Caffeine metabolism before and after liver transplantation. Int J Clin Pharmacol Ther (2001) 0.78
Determination of caffeine and its metabolites in urine by high-performance liquid chromatography and capillary electrophoresis. Scand J Clin Lab Invest (1994) 0.77
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS (2001) 5.52
Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol (1982) 2.49
Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG (2012) 2.14
Prevalence and determinants of QT interval prolongation in medical inpatients. Intern Med J (2012) 2.01
Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421". Lancet (1981) 1.99
Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. Br J Clin Pharmacol (1982) 1.95
Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels. Leukemia (2007) 1.89
Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects. Br J Clin Pharmacol (1981) 1.88
Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther (1981) 1.88
Risk factors of sensorineural hearing loss in preterm infants. Biol Neonate (1997) 1.63
Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther (2009) 1.57
Midazolam premedication reduces propofol dose requirements for multiple anesthetic endpoints. Can J Anaesth (2001) 1.55
Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol (1983) 1.54
A single LC-tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and their metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.48
Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol (2006) 1.46
Psychopharmacology in supportive care of cancer: a review for the clinician. III. Antidepressants. Support Care Cancer (2000) 1.45
Midazolam premedication and thiopental induction of anaesthesia: interactions at multiple end-points. Br J Anaesth (1999) 1.42
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.33
Disappearance rate of catecholamines, total metanephrines, and neuropeptide Y from the plasma of patients after resection of pheochromocytoma. Clin Chem (2001) 1.27
Diet acids and alkalis influence calcium retention in bone. Osteoporos Int (2001) 1.24
Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.20
Rate, type, and cost of adverse drug reactions in emergency department admissions. Eur J Intern Med (2001) 1.19
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer (2008) 1.13
Simultaneous determination of deoxyribonucleoside in the presence of ribonucleoside triphosphates in human carcinoma cells by high-performance liquid chromatography. Anal Biochem (1999) 1.12
Influence of perinatal, developmental and environmental factors on cognitive abilities of preterm children without major impairments at 5 years. Early Hum Dev (1995) 1.11
A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.10
Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interferon Cytokine Res (2000) 1.09
Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers. J Neuroimmunol (1999) 1.09
Trimethoprim, alone or in combination with sulphamethoxazole, decreases the renal excretion of zidovudine and its glucuronide. Br J Clin Pharmacol (1992) 1.08
Sinistrin clearance for determination of glomerular filtration rate: a reappraisal of various approaches using a new analytical method. J Clin Pharmacol (1997) 1.07
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Ann Oncol (1999) 1.04
Safety of oral immunisation with recombinant urease in patients with Helicobacter pylori infection. Lancet (1996) 1.03
The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: a randomized double-blind controlled trial. Ann Oncol (1999) 1.03
Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability. Ther Drug Monit (2001) 1.02
Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia. Dermatology (2005) 1.02
Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther (1992) 0.99
Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient. J Antimicrob Chemother (2004) 0.98
Lipid and lipoprotein profile in HIV-infected patients treated with lopinavir/ritonavir as a component of the first combination antiretroviral therapy. AIDS Res Hum Retroviruses (2010) 0.95
Drug points: severe ergotism associated with interaction between ritonavir and ergotamine. BMJ (1999) 0.93
Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. Eur J Pediatr (2000) 0.93
Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients. J Clin Pharmacol (2003) 0.92
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. Cancer Chemother Pharmacol (1998) 0.92
Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.91
Raised leptin concentrations at high altitude associated with loss of appetite. Lancet (1998) 0.91
Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension (1995) 0.91
Determination of aciclovir and ganciclovir in human plasma by liquid chromatography-spectrofluorimetric detection and stability studies in blood samples. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.90
Lithium infusion to study sodium handling in unanesthetized hypertensive rats. Hypertension (1986) 0.90
A simple, robust and rapid approach to detect carbapenemases in Gram-negative isolates by MALDI-TOF mass spectrometry: validation with triple quadripole tandem mass spectrometry, microarray and PCR. Clin Microbiol Infect (2014) 0.90
Validation of an HPLC method for the determination of urinary and plasma levels of N1-methylnicotinamide, an endogenous marker of renal cationic transport and plasma flow. J Pharm Biomed Anal (2001) 0.89
Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction. J Chromatogr B Biomed Appl (1995) 0.89
Dose-dependent effect of atrial natriuretic peptide on blood pressure, heart rate, and skin blood flow of normal volunteers. J Cardiovasc Pharmacol (1986) 0.89
Renal sodium handling in patients with untreated hypertension and white coat hypertension. Hypertension (1994) 0.88
Delta(9)-THC, 11-OH-Delta(9)-THC and Delta(9)-THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead people. Forensic Sci Int (2001) 0.88
Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.88
High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrob Agents Chemother (2010) 0.88
Blood pressure maintenance in awake dehydrated rats: renin, vasopressin, and sympathetic activity. Am J Physiol (1983) 0.87
Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur J Clin Pharmacol (1995) 0.87
Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations. J Hypertens (1990) 0.86
Characterization of a selective antagonist of neuropeptide Y at the Y2 receptor. Synthesis and pharmacological evaluation of a Y2 antagonist. J Biol Chem (1997) 0.86
Influence of debrisoquin phenotype on the inducibility of propranolol metabolism. Clin Pharmacol Ther (1989) 0.85
Estimation of glomerular filtration rate by sinistrin clearance using various approaches. Ren Fail (1998) 0.85
Right arm involvement and pain extension can help to differentiate coronary diseases from chest pain of other origin: a prospective emergency ward study of 278 consecutive patients admitted for chest pain. J Intern Med (1990) 0.85
Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment. Intensive Care Med (1998) 0.85
Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension (1995) 0.84
Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir. Antimicrob Agents Chemother (2009) 0.84
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction. J Chromatogr B Biomed Sci Appl (2000) 0.84
Clinical pharmacology of atrial natriuretic (3-28) eicosahexapeptide. J Hypertens Suppl (1986) 0.84